Holding(s) in Company

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 7 June 2017 by Aviva plc & its subsidiaries ("Aviva") that as at 6 June 2017 Aviva's direct interest in shares in the Company had changed. Aviva's total interest in the Company including its non-disclosable (indirect) position remains unchanged at 8,924,647 shares (4.5%). The full TR-1 disclosure is set out below.

For further information, please contact:

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Motif Bio plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

√

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

√

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

Available on Request 3,444*

Chase (GA Group) Nominees Limited 3,354,076*

HSBC Global Custody Nominee (UK) Limited 1,162,092*

State Street Nominees Limited 103,780*

*denotes direct interest

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

06 June 2017

6. Date on which issuer notified:

07 June 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

>3% to

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

GB00BVVT4H71

6,895,922*

6,895,922*

4,623,392

4,623,392

** Not Disclosable

2.36%

** Not Disclosable

*Includes Right to Recall Loaned Shares (1,000,006)

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

2,500,006*

*Direct interest

1.27%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,123,398

3.63%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited & Friends Provident International Limited, with the following chain of controlled undertakings:-

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Friends Provident International Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Friends Provident International Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

Figures are based on the revised total number of voting rights of 196,212,108 as per the Company's Exercise of Warrants and Issue of Equity announcement of 2 May 2017.

** Although not reportable, as per DTR5.1.5,the non-disclosable (indirect) position is currently 1,801,249 shares, and is included here in the interests of transparency.

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420